Lidbree

Lidocaine, the active ingredient in Lidbree, is a local anesthetic (amide) presented as an intrauterine formulation for intrauterine use. It provides local anesthesia for intrauterine procedures, helping to reduce discomfort during diagnostic or therapeutic interventions performed in the uterine cavity.

GNH USA supplies Lidbree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Lidocaine is a local anesthetic used to block nerve conduction during intrauterine procedures.

- Intrauterine surgery: provides localized anesthesia to reduce pain during operative hysteroscopy. - Diagnostic hysteroscopy: facilitates patient comfort while examining the uterine cavity. - Endometrial ablation: offers analgesia during tissue removal procedures.

Lidocaine may cause a range of adverse reactions when used intrauterinely.

Common Side Effects: - Uterine cramping - Vaginal spotting or mild bleeding - Mild nausea - Transient dizziness - Local irritation at the application site

Serious or Rare Side Effects: - Anaphylactic reaction (severe allergy) - Cardiac arrhythmia or conduction disturbances - Systemic lidocaine toxicity (CNS symptoms such as seizures) - Severe hypotension - Respiratory depression

Before using Lidbree, consider the following safety measures.

- Allergy assessment: verify no known lidocaine hypersensitivity. - Cardiac history: use with caution in patients with conduction disorders or severe arrhythmias. - Pregnancy: administer only if the expected benefit justifies potential risk to the fetus. - Concurrent medications: avoid simultaneous use with other local anesthetics to prevent cumulative toxicity. - Dosage: follow the prescriber’s specific instructions for volume and concentration. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lidbree may interact with other medicines; monitor patients accordingly.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): may increase lidocaine plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise systemic exposure.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance cardiac depressant effects. - General anesthetics (e.g., propofol): additive central nervous system depression. - Other local anesthetics: risk of cumulative toxicity.